![Douglas Blankenship](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Douglas Blankenship
Nessuna posizione attualmente
Patrimonio netto: 504 $ in data 31/05/2024
Profilo
Douglas L.
Blankenship is currently the Chief Financial Officer at Holdco Nuvo.
Group DG Ltd.
He previously worked as the Director-Global Quality, Compliance & Technical at Genentech, Inc. from 2006 to 2015, Director-Global Quality & Compliance at Roche Pharmaceuticals, Inc. from 2008 to 2015, Finance Director at Amgen Technology (Ireland) Unlimited Co. from 2006 to 2008, and CFO & Principal Accounting Officer at Dova Pharmaceuticals, Inc. from 2017 to 2018.
Mr. Blankenship obtained an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from The Wharton School of the University of Pennsylvania.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
0.00% | 01/05/2024 | 385 ( 0.00% ) | 504 $ | 31/05/2024 |
Posizioni attive di Douglas Blankenship
Società | Posizione | Inizio |
---|
Precedenti posizioni note di Douglas Blankenship
Società | Posizione | Fine |
---|---|---|
Humacyte Global, Inc.
![]() Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Direttore Finanziario/CFO | 19/05/2021 |
DOVA PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 31/01/2018 |
Roche Pharmaceuticals, Inc.
![]() Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Responsabile della Conformità | 01/10/2015 |
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/10/2015 |
Amgen Technology (Ireland) Unlimited Co.
![]() Amgen Technology (Ireland) Unlimited Co. Medical/Nursing ServicesHealth Services Part of Amgen, Inc., Amgen Technology (Ireland) Unlimited Co. is an Irish company committed to unlocking the potential of biology for patients suffering from serious illnesses. The company is based in Dublin, Ireland and is dedicated to serving patients by finding new solutions that improve lives through the potential of biology. With a robust pipeline and state-of-the-art science and molecular engineering, Amgen Technology (Ireland aims to create transformative medicines with large effects in serious diseases. The company, founded in 2006, focuses on developing and delivering transformative medicines to meet the needs of patients. | Direttore Finanziario/CFO | 01/01/2008 |
Formazione di Douglas Blankenship
California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Dova Pharmaceuticals, Inc.
![]() Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Roche Pharmaceuticals, Inc.
![]() Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Amgen Technology (Ireland) Unlimited Co.
![]() Amgen Technology (Ireland) Unlimited Co. Medical/Nursing ServicesHealth Services Part of Amgen, Inc., Amgen Technology (Ireland) Unlimited Co. is an Irish company committed to unlocking the potential of biology for patients suffering from serious illnesses. The company is based in Dublin, Ireland and is dedicated to serving patients by finding new solutions that improve lives through the potential of biology. With a robust pipeline and state-of-the-art science and molecular engineering, Amgen Technology (Ireland aims to create transformative medicines with large effects in serious diseases. The company, founded in 2006, focuses on developing and delivering transformative medicines to meet the needs of patients. | Health Services |
Humacyte Global, Inc.
![]() Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Douglas Blankenship